Breaking News Instant updates and real-time market news.

MDCO

The Medicines Co.

$33.01

-0.19 (-0.57%)

12:51
05/19/19
05/19
12:51
05/19/19
12:51

The Medicines Co. announces interim results from ORION-3 extension study

The Medicines Co. announced interim results from the ongoing ORION-3 open-label extension study, which showed that twice-a-year dosing with inclisiran sodium 300 mg resulted in consistent lowering of low density lipoprotein cholesterol by more than 50% with overall follow-up of up to three years. Inclisiran was well tolerated, and no material safety issues were observed in the study. These results were presented during a late-breaking clinical trial session at the National Lipid Association Scientific Sessions. Inclisiran, the first cholesterol-lowering therapy in the siRNA class, is in Phase 3 clinical development to evaluate its ability to lower LDL-C through twice-a-year dosing. Pivotal Phase 3 readouts for inclisiran are expected in the third quarter. ORION-3 is an open-label extension study of the Phase 2 ORION-1 trial to assess the efficacy, safety and tolerability of long-term dosing of inclisiran. In this interim analysis of ORION-3, inclisiran demonstrated a 51% reduction in LDL-C levels through day 210, which was the study's primary endpoint. The time-averaged absolute LDL-C reduction with inclisiran was 59.4 mg/dL. These effects were independent of dose level and number of doses of inclisiran previously given in the ORION-1 study. With overall follow-up of approximately three years from the first dose in ORION-1, no change in the overall safety profile was observed in this interim analysis of ORION-3 compared to the one-year follow-up in ORION-1. Inclisiran was well tolerated and no material safety issues were observed, including no elevations of liver enzymes or changes in renal function considered related to study medication. Clinically relevant injection site reactions were infrequent, mild or moderate, and transient, in line with observations in ORION-1.

  • 20

    May

MDCO The Medicines Co.
$33.01

-0.19 (-0.57%)

04/26/19
GSCO
04/26/19
UPGRADE
Target $55
GSCO
Buy
The Medicines Co. upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Paul Choi upgraded The Medicines Co. to Buy from Neutral and raised his price target for the shares to $55 from $25 ahead of the company's Phase III data in Q3.
04/26/19
GSCO
04/26/19
UPGRADE
Target $55
GSCO
Buy
Goldman Sachs sees 90% upside in Medicines Co., upgrades shares to Buy
Goldman Sachs analyst Paul Choi upgraded The Medicines Co. to Buy from Neutral and raised his price target for the shares to $55 from $25. The target implies 90% upside from the current price of $29.80. The analyst says that with the Orion Phase 3 topline results expected in Q3, his comfort level with inclisiran's benefit/risk profile has increased based on the recent updates from the independent data monitoring committee and a separate update for givosiran, which uses the same ESC-GalNAc conjugate platform. Further, new management is taking the appropriate steps to right-size the cost base and capital structure, Choi tells investors in a research note. This sets up inclisiran for a successful launch, which should also increase The Medicines Co.'s potential appeal to partner or strategic buyer, adds the analyst. Choi also thinks near term consensus launch expectations are achievable.
04/26/19
04/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Cleveland-Cliffs (CLF) upgraded to Outperform from Neutral at Credit Suisse with analyst Curt Woodworth saying he sees potential value near $16-$18 once the HBI plant is fully ramped, even with low hot-rolled coil prices at that point in time. 2. Argo Group (ARGO) upgraded to Outperform from Market Perform at William Blair with analyst Adam Klauber saying Argo is beginning to emerge as a long-term midcap growth insurer, Klauber tells investors in a research note. 3. Illinois Tool Works (ITW) upgraded to Neutral from Underweight at JPMorgan with analyst Ann Duignan saying following the company's "solid" Q1 results, downside risk to 2019 earnings estimates "appears limited," with the worst of auto builds and European weakness "likely behind us." 4. The Medicines Co. (MDCO) upgraded to Buy from Neutral at Goldman Sachs while Esperion (ESPR) upgraded to Neutral from Sell. 5. Shutterfly (SFLY) upgraded to Outperform from Market Perform at Raymond James with analyst Aaron Kessler citing stable Consumer segment growth trends and his expectation for improved consumer growth throughout 2019, as well as "very achievable" 2021 EBITDA guidance of $400M-$450M with modest organic growth assumptions and modest Lifetouch synergies baked in. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/02/19
SBSH
05/02/19
NO CHANGE
Target $23
SBSH
Buy
Amarin selloff creates attractive entry point, says Citi
Citi analyst Joel Beatty believes the selloff yesterday in shares of Amarin (AMRN) brings an attractive entry point. He raised his price target for the stock to $23 from $20 and keeps a Buy rating on the name. The analyst sees five potential upside catalysts this year, including a likely supportive ICER cost-effectiveness review and potential priority review from the FDA. Further, while an acquisition of Amarin is possible, the company acquiring The Medicines Co. (MDCO) or Esperion (ESPR) "could also be a viable path," says Beatty.

TODAY'S FREE FLY STORIES

NTES

NetEase

$262.82

0.42 (0.16%)

13:25
06/24/19
06/24
13:25
06/24/19
13:25
Options
NetEase call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$199.18

0.41 (0.21%)

13:21
06/24/19
06/24
13:21
06/24/19
13:21
Periodicals
Apple rolls out fifth iOS 12.4 beta ahead of Apple Card launch, 9to5Mac says »

Apple is rolling out the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
06/24/19
06/24
13:17
06/24/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFMD

Affimed N.V.

$2.97

-0.45 (-13.16%)

13:16
06/24/19
06/24
13:16
06/24/19
13:16
Hot Stocks
Affimed falls 13% after announcing clinical update on AFM13 in CD30 lymphomas »

Earlier today, Affimed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
06/24/19
06/24
13:16
06/24/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSIT

Insight Enterprises

$56.89

0.7 (1.25%)

, PCMI

PCM, Inc.

$34.67

10.315 (42.36%)

13:13
06/24/19
06/24
13:13
06/24/19
13:13
Recommendations
Insight Enterprises, PCM, Inc. analyst commentary at Stifel »

Insight Enterprises price…

NSIT

Insight Enterprises

$56.89

0.7 (1.25%)

PCMI

PCM, Inc.

$34.67

10.315 (42.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

NBL

Noble Energy

$21.32

-0.24 (-1.11%)

, OXY

Occidental Petroleum

$50.09

-0.53 (-1.05%)

13:07
06/24/19
06/24
13:07
06/24/19
13:07
Periodicals
U.S. natural gas prices plummet in June, Forbes says »

According to Jude…

NBL

Noble Energy

$21.32

-0.24 (-1.11%)

OXY

Occidental Petroleum

$50.09

-0.53 (-1.05%)

EOG

EOG Resources

$90.84

-1.57 (-1.70%)

DVN

Devon Energy

$27.93

-0.31 (-1.10%)

APA

Apache

$29.14

-0.52 (-1.75%)

CHK

Chesapeake

$1.89

-0.055 (-2.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 02

    Aug

  • 27

    Aug

  • 13

    Nov

D

Dominion

$79.35

1.01 (1.29%)

13:05
06/24/19
06/24
13:05
06/24/19
13:05
Options
Dominion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDS

Aridis Pharmaceuticals

$9.65

-0.55 (-5.39%)

13:04
06/24/19
06/24
13:04
06/24/19
13:04
Hot Stocks
Aridis' treatment of lung infections in CF patients granted orphan designation »

Aridis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELF

e.l.f. Beauty

$13.37

0.3 (2.30%)

, COTY

Coty

$13.09

-0.12 (-0.91%)

13:02
06/24/19
06/24
13:02
06/24/19
13:02
On The Fly
Ulta, Sally Beauty slide after Amazon announces Professional Beauty Store »

Shares of Ulta Beauty…

ELF

e.l.f. Beauty

$13.37

0.3 (2.30%)

COTY

Coty

$13.09

-0.12 (-0.91%)

REV

Revlon

$21.48

-0.65 (-2.94%)

EL

Estee Lauder

$183.51

2.21 (1.22%)

AMZN

Amazon.com

$1,907.03

-3.39 (-0.18%)

SBH

Sally Beauty

$12.83

-1.96 (-13.25%)

ULTA

Ulta Beauty

$342.74

-13.03 (-3.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 01

    Jul

  • 09

    Jul

  • 10

    Jul

  • 19

    Aug

  • 29

    Aug

MCRB

Seres Therapeutics

$2.99

0.31 (11.57%)

, PSEC

Prospect Capital

$6.62

0.02 (0.30%)

13:01
06/24/19
06/24
13:01
06/24/19
13:01
On The Fly
Fly Insider: Seres, Tiffany among week's notable insider transactions »

Welcome to "Fly Insider,"…

MCRB

Seres Therapeutics

$2.99

0.31 (11.57%)

PSEC

Prospect Capital

$6.62

0.02 (0.30%)

SGMS

Scientific Games

$18.30

-0.69 (-3.63%)

FCNCA

First Citizens

$437.76

2.47 (0.57%)

PBF

PBF Energy

$27.64

-0.825 (-2.90%)

GIII

G-III Apparel

$27.96

0.04 (0.14%)

TIF

Tiffany

$92.98

-0.66 (-0.70%)

NVDA

Nvidia

$153.37

1.63 (1.07%)

ZAYO

Zayo Group

$33.00

-0.04 (-0.12%)

WRB

W. R. Berkley

$67.11

0.23 (0.34%)

ZBRA

Zebra Technologies

$201.50

1.35 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 15

    Aug

BCOM

B Communications Ltd.

$1.90

0.05 (2.70%)

12:59
06/24/19
06/24
12:59
06/24/19
12:59
Hot Stocks
B Communications Ltd. says board approves Searchlight transaction »

B Communications Ltd.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$288.53

-5 (-1.70%)

12:55
06/24/19
06/24
12:55
06/24/19
12:55
Options
Anthem put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

MNK

Mallinckrodt

$8.57

-0.39 (-4.35%)

12:40
06/24/19
06/24
12:40
06/24/19
12:40
Options
Mallinckrodt call block opens $5M long-dated position 110% above spot »

Mallinckrodt call block…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

BZUN

Baozun

$48.07

-1.33 (-2.69%)

12:35
06/24/19
06/24
12:35
06/24/19
12:35
Options
Baozun put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$62.66

-1.1 (-1.73%)

12:25
06/24/19
06/24
12:25
06/24/19
12:25
Conference/Events
Cubic to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

FB

Facebook

$193.26

2.1 (1.10%)

12:23
06/24/19
06/24
12:23
06/24/19
12:23
Periodicals
Facebook's Clegg dismisses calls for break-up, Reuters says »

Facebook's head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 16

    Jul

JMIA

Jumia Technologies

$25.42

-0.26 (-1.01%)

12:20
06/24/19
06/24
12:20
06/24/19
12:20
Periodicals
Jumia Food eyes Africa's middle class to boost growth, Reuters says »

Jumia Food, Jumia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETFC

E-Trade

$44.83

-1.4 (-3.03%)

12:20
06/24/19
06/24
12:20
06/24/19
12:20
Options
E Trade put seller opens August 40 strike position »

E Trade put seller opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

T

AT&T

$32.59

0.13 (0.40%)

12:18
06/24/19
06/24
12:18
06/24/19
12:18
Hot Stocks
AT&T's WarnerMedia appoints Ann Sarnoff CEO of Warner Bros. »

WarnerMedia CEO John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

FTD

FTD Companies

$0.00

(0.00%)

12:17
06/24/19
06/24
12:17
06/24/19
12:17
Hot Stocks
FTD Companies enters into asset purchase agreement for Personal Creations »

FTD Companies provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
06/24/19
06/24
12:17
06/24/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
06/24/19
06/24
12:16
06/24/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$45.94

-3.42 (-6.93%)

, CELG

Celgene

$93.98

-4.94 (-4.99%)

12:15
06/24/19
06/24
12:15
06/24/19
12:15
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks are mildly higher…

BMY

Bristol-Myers

$45.94

-3.42 (-6.93%)

CELG

Celgene

$93.98

-4.94 (-4.99%)

ERI

Eldorado Resorts

$45.74

-5.48 (-10.70%)

CZR

Caesars

$11.52

1.53 (15.32%)

PCMI

PCM, Inc.

$34.71

10.36 (42.55%)

NSIT

Insight Enterprises

$57.56

1.37 (2.44%)

KRYS

Krystal Biotech

$37.20

7.92 (27.05%)

SBH

Sally Beauty

$12.94

-1.85 (-12.51%)

AMZN

Amazon.com

$1,909.00

-1.42 (-0.07%)

WAB

Wabtec

$68.53

-4.22 (-5.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 24

    Jun

  • 24

    Jun

  • 24

    Jun

  • 25

    Jun

  • 25

    Jun

  • 27

    Jun

  • 02

    Jul

  • 10

    Jul

  • 25

    Jul

  • 03

    Sep

  • 16

    Sep

  • 13

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

SRPT

Sarepta

$128.78

-1.13 (-0.87%)

12:15
06/24/19
06/24
12:15
06/24/19
12:15
Options
Sarepta put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.